A Phase II Study of SGN-40 (Anti-huCD40 mAb) in Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)
This is a Phase II, open-label, multidose trial of SGN-40 designed to estimate objective response rate and assess toxicity in patients with relapsed DLBCL.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- drug : SGN-40
Phase: Phase 2
Ages Eligible For Study:
- Diagnosis of DLBCL. - Received at least one combination chemotherapy regimen with rituximab, such as R-CHOP, R-ESHAP or equivalent. - Progression or relapse since most recent therapy. - At least one measurable lesion that is both greater than or equal to 2 cm by conventional CT or greater than or equal to 1.5 cm by spiral CT.